Merck's DME Trial Yields Positive Results, Raises Safety Concerns
Merck & Co.'s Brunello trial for remiglomin in adults with diabetic macular edema (DME) has yielded positive top-line data, but a potential safety issue is casting a shadow over the results. The phase IIb/III trial showed that remiglomin significantly improved visual acuity compared to the control group.
However, Merck & Co.'s Brunello trial also highlighted a possible red flag regarding safety. Despite the positive top-line data, the company noted a higher incidence of an adverse event in the treatment group than in the control group.
Surrozen Inc., a competitor of Merck & Co., has seen its stock price increase due to the news from Brunello trial. Backers of Surrozen are likely feeling optimistic about their own prospects, given the positive results from the trial.